agonal phase of monoolein and also reported another successful application with the combination of vitamin K estimated log K octanol/water : 11.7 and MW: 451 and hexagonal phase of monoolein 8 . Furthermore, in our previous studies 13 , 14 , we demonstrated successful improvement in drug absorption after oral and transdermal application with LC formulations that composed with glyceryl 5,9,13-trimethyltetradec-4-enoate MGE; Fig. 1 , and the enhancement effect of these formulations was dramatically affected by the type of LC-forming lipids. MGE was easy-to-handle due to its low viscosity at 25 compared to glyceryl monooleate GMO and phytantriol PHT and it showed better drug absorption enhancement effects. However, no studies have investigated the effect of several factors such as physiochemical properties of the entrapped drugs and concentration of LC-forming lipids and LC phase structure on the enhancement effect of orally and topically administered drugs. Therefore, in the present study, MGE was selected as an LC-forming lipid. p-Amino benzoic acid PABA and its prodrugs, methyl p-aminobenzoate M-PABA and ethyl p-aminobenzoate E-PABA Table 1 were selected as drug models with different lipophilicities to understand the effect of the lipophilicity changes on the drug absorption performance of LC formulations. On the other hand, for transdermal LC formulations, only hydrophilic sodium fluorescein Na-FL was selected as a model drug and was entrapped with different concentrations of MGE. Overcoming the stratum corneum barrier to cutaneously deliver hydrophilic drugs is one of the major challenges in the field of dermatologic therapy; therefore, Na-FL was used as a wellknown hydrophilic and mal-absorbed model drug in this study. Thus, in the present study we aimed to develop strategies for designing and optimizing oral and topical LC formulations by evaluating the effect of these factors on the drug absorption from LC formulations.
Materials and methods

Materials
MGE purity: 99.56 was obtained from Farnex Co., Inc. Yokohama, Japan . PABA, M-PABA, and E-PABA were purchased from Kanto Chemical Co., Inc. Tokyo, Japan . Na-FL was purchased from Tokyo Chemical Industry Co., Ltd. Tokyo, Japan . A surfactant, Pluronic ® F127, was purchased from Sigma-Aldrich St. Louis, MO, USA . Other reagents and solvents were of special grade or HPLC grade and used without further purification. Table 2 lists the oral and topical LC formulations used in this study. These formulations were designed based on changing the concentration of MGE in the formulations and entrapped with drugs with different physiochemical properties. The mixture was dispersed using a homogenizer Polytron PT-MR 3000; Kinematica Inc., Littau, Switzerland . The dry powder LC formulations were prepared using a freeze dryer Labcono FZ-18; Asahi Life Science Co. Ltd., Tokorozawa, Saitama, Japan .
Preparation of oral and topical LC formulations
Measurement of particle size and zeta potential
The particle size and zeta potential of LC formulations were determined using a dynamic light scattering Nano-ZS ZEN3600 Zetasizer Malvern Instruments Ltd., Worcestershire, U.K. . LC samples were diluted in distilled water and shaken using a vortex mixer prior to measurement. 
SAXS measurement
SAXS measurement of dispersed formulations was performed using a Nano-Viewer Rigaku, Tokyo, Japan with a Pilatus 100K/RL 2D detector. The X-ray source was Cu Kα radiation with a wavelength of 1.54 Å and operating at 45 kV and 110 mA. The sample-to-detector distance was set at 375 mm. Each sample was placed into a vacuum-resistant glass capillary cell and exposed at 25 for 10 min. The SAXS pattern obtained was plotted against the scattering vector length, q 4π/λ shin θ/2 where θ is the scattering angle.
Release experiment
A dialysis membrane molecular weight cut-off; 2,000-14,000 Da, Sanko Junyaku Co., Tokyo, Japan was set in a vertical-type diffusion cell effective diffusion area: 0.95 cm 2 and the receiver chamber was maintained at 32 .
Phosphate-buffered saline PBS; pH 7.4 was applied to the receiver chamber. Drug PABA, M-PABA, E-PABA or Na-FL solution 1.0 mL or its LC formulation 1.0 mL was applied to the donor cell to start the release experiment. An aliquot 500 µL was withdrawn from the receiver chamber, and the same volume of PBS was added to the chamber to keep the volume constant. The amount of PABA, M-PABA, and E-PABA released was determined using an HPLC Shimadzu Ltd., Kyoto, Japan . In case of Na-FL, the released amount was determined using a fluorescence spectrophotometer Shimadzu Ltd., Kyoto, Japan . The cumulative of drug released was plotted against the square root of time Higuchi s plot 15 .
Animals
Male hairless WBM/ILA-Ht and male Wistar Slc rats were purchased either from Life Science Research Center, Josai University Sakado, Saitama, Japan or Ishikawa Experiment Animal Laboratories Fukaya, Saitama, Japan . Animals were housed in temperature-controlled rooms 25 2 with a 12 h light-dark cycle 07:00-19:00 h . The rats were allowed free access to food Oriental Yeast Co., Tokyo, Japan and tap water. The animal experiment protocol was approved by the Animal Care and Use Committee of Josai University Sakado, Saitama, Japan .
HPLC conditions
The in vivo or in vitro study sample 50 µL was mixed with the same volume of acetonitrile to precipitate plasma proteins containing methyl paraben 10 µg/mL as an internal standard and centrifuged 5 min, 4 . The obtained supernatant 20 µL was injected into an HPLC system Shimadzu, Kyoto, Japan , which consisted of a system controller CBM-20A , pump LC-20AD , auto-sampler SIL-20AC , column oven CTO-20A , UV detector SPD-M20A , and analysis software LC Solution . The column was an GL Sciences Inc. ODS-3 5 µm, 4.6 250 mm Nihon Waters K.K., Tokyo, Japan , which was maintained at 40 . The mobile phase was acetonitrile : 0.1 phosphoric acid 8 : 52 0-4 min , 35 : 65 4-14 min and 8 : 92 14-20 min . The flow rate was adjusted to 1.0 mL/min. PABA, M-PABA, and E-PABA were detected at UV 280 nm.
Determination of bioavailability
Intravenous and oral administrations were performed in Wistar rats under anesthesia by intraperitoneal injection of three types of anesthesia medetomidine, 0.375 mg/kg; butorphanol, 2.5 mg/kg; and midazolam, 2 mg/kg to determine the bioavailability of PABA. In case of intravenous administration, PABA dissolved in physiological saline PABA solution was injected 5 µmol/kg into the tail vein. Blood samples 0.2 mL were collected from the jugular vein at predetermined intervals up to 3 h, and the same volume of saline was injected via the tail vein to prevent severe changes in the volume of distribution. For oral administration, PABA solution or LC-formulation 10 µmol/kg was administered to rats, and blood 0.2 mL was withdrawn from the jugular vein at intervals up to 6 h and the same volume of saline was injected via tail vein. Blood samples placed into heparinized tubes were immediately separated by centrifugation to obtain plasma 5 min, 4 . Plasma and skin samples were stored at 30 until analysis.
In vitro skin permeation experiment
Full-thickness hairless rat skin was excised from the abdomen under anesthesia by i.p. injection of three types of anesthesia as above. Excess fat was trimmed off, and the skin samples were set in vertical-type diffusion cells with the epidermis side facing the donor compartment. PBS was applied to the receiver chamber as in the release experiment and maintained at 32 . These skin permeation experiments were conducted after hydration for 60 min with PBS. Drug solution 1.0 mL or its LC-formulation 1.0 mL was applied to the donor cell to start the in vitro skin permeation experiment. An aliquot 500 µL was withdrawn from the receiver chamber, and the same volume of PBS was added to the chamber to keep the volume constant. The skin permeation of Na-FL was determined using a fluorescence spectrophotometer.
Determination of AUC
The area under the plasma concentration-time curve AUC was calculated using the linear trapezoidal rule. The absolute bioavailability was determined as AUC po /AUC iv using the mean AUC values for oral and intravenous doses.
Statistical analysis
Statistical analysis was performed using unpaired Student s t-test ANOVA , and p values less than 0.05 were considered to be significant.
Results
Homogeneity and visible appearance
First, the homogeneity and visible appearance of the prepared LC formulations were evaluated. Accepted formulations were a uniform opaque white mixture or uniform powder without visible signs of aggregates, whereas rejected formulations appeared as a non-uniform dispersion or aggregated wet powder. Figure 2 shows photographs to illustrate these criteria for accepted and rejected formulations. OP30, OM30, and OE30 were inconvenient for oral due administration because of the high percentage of lipid creamy formulations ; therefore, these formulations were not studied for oral administration. However, these formulations were accepted for topical application TF30 and TF40 . Non-uniform mixtures with aggregates were observed with a high percentage of LC-forming lipid 40 ; therefore, no further work was carried out with these formulations. Fine powders were obtained in OP10D, OM10D, and OE10D. However, when the MGE content increased to 20 OP20D, OM20D, and OE20D, respectively , aggregated wet powders were observed. Therefore, no further work was carried out with them.
3.2 Particle size and zeta potential measurement Table 3 shows particle size and zeta potential values of oral and topical LC formulations. The obtained results showed that the particle size tended to be smaller and the zeta potential became more negative with increasing MGE content. Formulations with low MGE content represented by 5 i.e., OP5, OM5, OE5, and TF5 tended to have large particle size and low negative surface charge. Because the low surface charge indicated low stability of the 5 MGE Accepted formulations were appeared as a uniform opaque white mixture or uniform powder without visible signs of aggregates, while rejected formulations were appeared as a non-uniform dispersion or aggregated wet powder. formulations, no further work was carried out with these formulations. Figure 3a -d shows the release profile of PABA, M-PABA, E-PABA, and Na-FL, respectively, from their LC formulations. All profiles obeyed Higuchi s law 15 : high correlation coefficients r 0.99 were obtained for each formulation, indicating that in vitro drug release profiles of drug were fitted well with the square root Higuchi model. For oral formulations, the amounts of PABA released from OP10D, OP10, OP20, and OP30 were 13.9 2.5 , 23.7 3.2 , 16.7 2.8 , and 9.6 0.8 Fig. 3a , respectively, against the initial dosing. Those of M-PABA from OM10D, OM10, OM20, and OM30 were 6.4 0.4 , 5.7 0.3 , 4.2 0.2 , and 3.4 0.4 Fig. 3b , respectively, and those of E-PABA from OM10D, OM10, OM20, and OM30 were 3.8 0.3 , 3.4 0.3 , 2.5 0.2 , and 2.2 0.2 Fig. 3c , respectively. For topical formulations, the amounts of Na-FL released from TF10, TF20, TF30, and TF40 were 18 0.6 , 15.5 0.7 , 11.5 0.6 , and 6 0.7 Fig. 3d , respectively. Although the release profile was influenced by changes in the MGE concentration, it was influenced more dramatically by changes in the physiochemical properties of the entrapped drugs. For example, the release amount of Na-FL from TF10 was 18 0.6 Fig. 3d as compared with the release of E-PABA from OE10, 3.8 0.3 Fig. 3c , although both formulations contained the same concentration of MGE.
Drug release properties from LC formulations
SAXS chart of LC formulations
The phase structure of LC formulations was evaluated by SAXS. Figure 4a -c shows the X-ray diffraction profiles Fig. 4a , OP20 Fig. 4b , and OM10 Fig. 4c formulations. Typical peaks reflection distance ratios at nearly 1, 3, and 4, revealed the presence of an H 2 inverted hexagonal phase. The same peaks reflection distance ratios were observed for OM20, OE10, OE20, TF10, TF20, TF30, and TF40 data not shown . The phase behavior of these formulations was determined based on international tables for crystallography 16, 17 . Unidentified peaks were observed for oral dry powder LC formulations OP10D Fig. 4d , OM10D Fig. 4e and OE10D Fig. 4f . Figure 5 shows the time course of the plasma concentration of PABA after intravenous injection and Fig. 6 shows formulation; e , OM10D formulation and f , OE10D formulation. The peaks reflection distance ratios at: 1, 3, 4 confirming the presence of H 2 inverted hexagonal phase a-c , the same peaks reflection distance ratios were observed for OM20, OE10, OE20, TF10, TF20, TF30 and TF40 data were not shown . Unidentified peaks were observed for dry powder LC formulations d-f .
Bioavailability of PABA
the time course of the plasma concentration of PABA after oral administration of its solution or PABA-, M-PABA-, and E-PABA-LC formulations in male Wistar rats. Table 4 summarizes the calculated AUC 0-6 h , T max , C max , and absolute bioavailability F of PABA after oral administration. The bioavailability after oral administration of OP20 55 13 Fig. 6a , OM10 44 9 Fig. 6b , and OE10 43 6 Fig. 6c was significantly higher than that of PABA solution 16 2 . No improvement was observed in the bioavailability for other LC formulations. The T max of OP20 was faster compared with OM10 and OE10. The T max of OE10 was delayed to 120 min. Only OP20, OM10, and OE10 showed significant improvement in the bioavailability of PABA. M-PABA, and E-PABA prodrugs after oral administration. Figure 7 shows the effect of LC formulations on the time course of the cumulative amount of Na-FL that permeated through hairless rat intact skin. Significant improvements in skin permeation of Na-FL was observed after application of TF20 and TF30 compared with that from the Na-FL solution. The enhancement ratios in the skin permeation for TF10, TF20, and TF30 formulations were 1.7, 4.3, and 2.9, respectively, but no improvement in skin permeation of the Na-FL was observed with TF40 formulation.
In vitro skin permeation pro les
Discussion
Although LC formulations have received considerable attention because of their excellent potential as drug delivery systems 6 , there seems to be a general lack of understanding among researchers regarding the effect of several factors such as physiochemical properties of the entrapped drugs, concentration of LC-forming lipids and LC phase structure on the oral and topical performance of these formulations. Therefore, the present study mainly focused on the developing strategies of oral and topical LC formula- tions by investigating the effect of such factors to improve the performance of these formulations.
MGE was selected an LC forming lipid because of its low viscosity, stability and better drug absorption enhancer compare with other LC forming lipids 13 . We initially screened various oral and topical LC formulations Table  2 . The obtained results on their homogeneity and visible appearance Fig. 2 showed that it was not recommended to prepare oral LC dispersions with MGE at a concentration of more than 30 , because these formulations tended to be too viscous and inconvenient for oral administration. When the concentration of MGE was above 40 , LC was aggregated with phase separation, therefore, they were inconvenient for both oral and topical formulations. In addition, MGE was not recommended to prepare LC dry powder at a concentration of 20 or above. Zeta potential is an important parameter for the evaluation of stability and bio-distribution 18, 19 . By increasing the MGE concentration, the particle size tended to be smaller and the zeta potential became more negative Table 3 , suggesting that the number of LC forming particles was increased with an increasing of MGE concentration. The negative zeta potential of LC formulations was due to the present of free oleic acid in the lipid phase. The negative charge can also be explained by preferential adsorption of hydroxyl ions at the lipid-water interface.
As demonstrated in Fig. 3 , the drug release profiles from LC formulations were influenced by the concentration of MGE and the physiochemical properties of the entrapped drugs. These results indicated that the drug diffusivity in the formulation decreased with an increase in MGE concentration. The drug diffusivity was affected more dramatically by changes in the physiochemical properties of entrapped drugs. The released amount of Na-FL from TF10 was 18 0.6 compared with the release of E-PABA from OE10 3.8 0. 3 , although both formulations contained the same concentration of MGE Fig. 3a-d . A similar phenomenon was observed with other drugs PABA and M-PABA , and drug release decreased with an increase in lipophilicity. Figure 8 schematically explains the effect of Typical reflection patterns at nearly 1, 3, and 4 for oral dispersions and topical LC formulations indicated that these formulations successfully managed to form an H 2 inverted hexagonal phase Fig. 4a-e . Previous studies 20, 21 have reported that the hexagonal phase has several advantages. It has a larger surface area to interact with biological membranes with high fluidity, and greater amounts of drugs can be incorporated independent of their solubility. In contrast to our findings, other studies have demonstrated the presence of cubosomes using different types of LCforming lipids such as glyceryl monooleate GMO or phytantriol PHT 10, 22 . We strongly believed that several factors might affect the phase structure of LC formulations, such as temperature, type of LC-forming lipid, physiochemical properties of the entrapped drugs, lipid concentration, and type of surfactant. Further studies are necessary to understand in full the effect of such factors on the phase transition of LC formulations. The key point is to successfully prepare hexosomes or cubosomes by design with LC formulations. No clear mechanism or clear evidence has been proposed to indicate that cubosomes have more potential than hexosomes, or vice versa, as a drug delivery system. On the other hand, unidentified peaks were observed in the SAXS measurement of oral dry powder formulations Fig. 4e-f . The drug absorption from oral LC formulations was dramatically affected by the MGE concentration and the physiochemical properties of entrapped drugs Fig. 6 . The bioavailability of PABA was significantly improved by the 20 MGE formulation OP20 compared with other LC formulations or PABA solution alone Fig. 6a . These results indicated that the rate limiting step in the absorption of hydrophilic drugs must be the permeating process through the intestinal membrane. Thus, the hexosome particles in contact with the small intestine were high in this formulation OP20 by increasing the MGE concentration.
In contrast, in case of M-PABA and E-PABA entrapping formulations, a low concentration of MGE OM10 and OE10 significantly improved the bioavailability of PABA compared with other LC formulations or PABA solution alone Fig. 6b and c . These results indicated that the rate limiting step in the absorption process for lipophilic drugs with LC formulations must be their release rate. Thus, the release amount of these drugs increased from these formulation OM10 and OE10 by decreasing the MGE concentration. This could be also the reason why the absorption of M-PABA and E-PABA from the LC formulations were delayed compared with PABA-LC formulation Table 4 . Furthermore, M-PABA and E-PABA were metabolized to PABA after oral administration of their LC formulations, indicating that LC systems were unable to protect these drugs from intestinal esterase metabolite activity.
Dry powdered oral LC formulations did not manage to form hexosomes or cubosomes, which could be a reason why these formulations were unable to improve the bioavailability of PABA.
In consequence, the same as in the in vivo oral absorption, in vitro skin permeation results were dramatically affected by the MGE concentration. Significant improvement in the skin penetration of Na-FL was observed in 20 and 30 MGE TF20 and TF30 with enhancement ratios of 4.3 and 2.9, respectively. However, no marked improvement was observed in 10 and 40 MGE, suggesting that a low concentration of MGE such as 10 TF10 could lead to a reduction in hexosomes particles. Thus it is necessary to overcome the barrier function of stratum corneum. On the other hand, a high concentration of MGE such as 40 TF40 reduced drug release from the formulation Fig. 7 . The detailed mechanism of the enhanced oral drug absorption and transdermal drug penetration by LC systems is not fully understood yet 9, 23 . Further studies must be conducted to clarify the absorption-enhancing mechanism of LC formulations.
Conclusion
The present data showed that LC formulations are promising to improve oral absorption and transdermal penetration of drugs. Our findings showed that the concentrations of LC-forming lipid and the physiochemical properties of entrapped drugs are very important factors that should be considered by researchers in this field to improve the performance of LC formulations in various pharmaceutical applications. Understanding the effect of these factors on LC formulation performance could enable researchers to develop LC formulation approaches that intended to improve the oral absorption and skin permeation of drugs.
